| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 39822-2200-01 | 39822-2200 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Apr 17, 2017 | Jul 31, 2020 | In Use |
| 00069-9144-11 | 00069-9144 | Docetaxel | Docetaxel | 200.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jun 23, 2014 | Apr 30, 2017 | No Longer Used |
| 66758-0950-03 | 66758-0950 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 22, 2015 | In Use | |
| 73358-0210-08 | 73358-0210 | Docetaxel Anhydrous | Docetaxel Anhydrous | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 17, 2022 | In Use | |
| 68001-0651-37 | 68001-0651 | Paclitaxel | Paclitaxel protein-bound particles for injectable suspension (albumin-bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 18, 2025 | In Use | |
| 83513-0010-01 | 83513-0010 | Docetaxel | BEIZRAY | 20.0 mg/ml | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 23, 2024 | In Use | |
| 67457-0937-50 | 67457-0937 | PACLITAXEL | PACLITAXEL | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 9, 2025 | In Use | |
| 73358-0210-16 | 73358-0210 | Docetaxel Anhydrous | Docetaxel Anhydrous | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 17, 2022 | In Use | |
| 23155-0884-31 | 23155-0884 | Paclitaxel | PACLITAXEL | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 31, 2023 | In Use | |
| 55390-0304-05 | 55390-0304 | Paclitaxel | Paclitaxel | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec 1, 2006 | Apr 30, 2013 | No Longer Used | |
| 16729-0120-49 | 16729-0120 | Docetaxel | Docetaxel | Chemotherapy | Antimitotic Agent | Taxane | Jun 30, 2011 | Jun 18, 2018 | No Longer Used | ||
| 83513-0009-01 | 83513-0009 | Docetaxel | BEIZRAY | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 23, 2024 | In Use | |
| 00703-4766-01 | 00703-4766 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 24, 2008 | Aug 31, 2019 | No Longer Used |
| 69339-0229-05 | 69339-0229 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Nov 7, 2024 | Jan 18, 2025 | In Use |
| 66758-0050-01 | 66758-0050 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jun 29, 2011 | In Use | |
| 66758-0043-03 | 66758-0043 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 2, 2008 | Feb 7, 2016 | In Use |
| 82959-0112-01 | 82959-0112 | imetelstat sodium | RYTELO | 47.0 mg/1 | Chemotherapy | Enzyme Inhibitor | Telomerase | Intravenous | Jun 6, 2024 | In Use | |
| 82959-0111-01 | 82959-0111 | imetelstat sodium | RYTELO | 188.0 mg/1 | Chemotherapy | Enzyme Inhibitor | Telomerase | Intravenous | Jun 6, 2024 | In Use | |
| 00781-2693-44 | 00781-2693 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
| 00527-1781-55 | 00527-1781 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 23, 2016 | May 24, 2018 | In Use |
| 51862-0084-51 | 51862-0084 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 10, 2016 | Mar 31, 2019 | In Use |
| 47335-0890-72 | 47335-0890 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
| 62175-0244-19 | 62175-0244 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 10, 2016 | In Use | |
| 23155-0778-71 | 23155-0778 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jun 15, 2022 | Jun 15, 2022 | No Longer Used |
| 65162-0805-51 | 65162-0805 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 3, 2015 | In Use |
Found 12250 results — Export these results
Home